Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG-1 zongertinib dose-finding study in advanced HER2-altered solid tumors
NL-OMON59945Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of zongertinib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Jul 2021; status: active, not recruiting.
02
Drugs
zongertinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59945.